Ionis hsd17b13
Web20 dec. 2024 · To assess the association of HSD17B13 rs72613567:TA allelic variant with liver disease, we performed the current review and meta-analysis. Seven studies were identified by a search of CNKI,CBM,MEDLINE, PubMed, EMBASE, and CENTRAL databases from inception to November 2024. Odds ratios (ORs) with 95% confidence … Web3 aug. 2024 · ALN-HSD is an investigational, subcutaneously administered RNAi therapeutic targeting HSD17B13 in development in collaboration with Regeneron Pharmaceuticals for the treatment of nonalcoholic ...
Ionis hsd17b13
Did you know?
Web22 mrt. 2024 · Association of HSD17B13 rs72613567 with Aminotransferase Levels in Persons with Each PNPLA3 p.I148M Genotype. Figure 3. Web7 jan. 2024 · Recently, HSD17B13, a newly identified liver-enriched, hepatocyte-specific, lipid droplet-associated protein, has been reported to be strongly associated with the development and progression of NAFLD/NASH in both mice and humans.
Web25 jun. 2024 · MODULATORS OF HSD17B13 EXPRESSION - IONIS PHARMACEUTICALS INC Title: MODULATORS OF HSD17B13 EXPRESSION Document Type and Number: WIPO Patent Application WO/2024/132564 Kind Code: A1 Abstract: Methods, compounds, and compositions useful for inhibiting HSD17B13 expression are … Web2 nov. 2024 · 17β-hydroxysteroid dehydrogenase-13 is a hepatocyte-specific, lipid droplet-associated protein. A common loss-of-function variant of HSD17B13 (rs72613567: TA) protects patients against non ...
Web23 apr. 2024 · HSD17B13 RNAi I NCT04202454 ARO-HBV / JNJ-3989 Hepatitis B HBV mRNA RNAi I NCT04208386 ATU027 Solid tumours/ advanced pancreatic cancer … Web30 jun. 2024 · HSD17B13 is a lipid droplet-associated protein, but its function is still ambiguous. Compared to the other genetic variants that increase risk for FLD, HSD17B13 variants serve a protective role, making this gene a potential therapeutic target. However, the mechanism by which these variants reduce the risk of developing FLD is still unclear.
Web26 nov. 2024 · The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. Sun DQ, et al. Nutr Metab Cardiovasc Dis, 2024 Jun 7. PMID 33853719 Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi …
Web30 mrt. 2024 · The HSD17B13 protein having SEQ I D NO:21 (Isoform A) is 300 amino acids in length. The HSD17B13 protein having SEQ ID NO:22 (Isoform B) is 264 amino … smart coffee table egyptWeb15 jun. 2024 · Hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), which was newly identified as a liver lipid droplet associated protein, was recently found to be down … hillcrest platte city moWeb7 jan. 2024 · Recently, HSD17B13, a newly identified liver-enriched, hepatocyte-specific, lipid droplet-associated protein, has been reported to be strongly associated with the development and progression of NAFLD/NASH in both mice and humans. hillcrest powerschoolWeb26 nov. 2024 · Title: HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance … hillcrest plastic surgery orlando flWebALN-HSD is a subcutaneously administered, investigational RNAi therapeutic targeting HSD17B13 for the treatment of non-alcoholic steatohepatitis (NASH), in collaboration … hillcrest plumbing and heating leedsWeb29 mrt. 2024 · As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and … Ionis Innovation Ionis’ antisense technology With RNA as the target that forms the … Ms. Cadoret-Manier is executive vice president, chief global product strategy … Our platform technology has served as a springboard for drug discovery and … Meet Fred and Lynne. For almost 40 years, the couple did not have a name for … The Investor Relations website contains information about Ionis … From the moment of our founding, we knew that we could transform the … IONIS-MAPT Rx, also known as BIIB080, is an investigational antisense medicine … Ion-ARPA programs will be funded (up to $1M per laboratory) based on high … smart coffee mugsWeb23 sep. 2024 · For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense … hillcrest pocahontas ar